AIM: To develop and validate a nomogram to estimate the probability of prostate cancer (PCa) in men undergoing opportunistic screening.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PATIENTS AND METHODS: This was a cross-sectional observational study on a cohort of men screened for PCa at the Barretos Cancer Hospital (BCH) between January 2004 and December 2007. Patients' data were collected from their charts and binary logistic regression analyses were performed to assess the power of various factor combinations as predictors of the PCa risk.
RESULTS: Out of the 1,313 screened men who underwent prostate biopsy, 553 (42.1%) had histopathological confirmation of PCa. The logistic regression analyses provided an area under the receiver operating characteristics (ROC) curve (AUC) of 0.737 (95% confidence interval (CI)=0.678-0.796) for the best predictor combination. A nomogram was constructed to estimate the individual risk for PCa prior to biopsy.
CONCLUSION: Our nomogram provides an easy and practical method, superior in performance to the traditional criteria, predicting the diagnosis of PCa with a reasonable accuracy.
Silva TB, Oliveira CZ, Faria EF, Mauad EC, Syrjänen KJ, Carvalho AL. Are you the author?
Department of Cancer Prevention, Barretos Cancer Hospital, Barretos, SP, Brazil; Teaching and Research Institute, Barretos Cancer Hospital, Barretos, SP, Brazil; Department of Surgery/Urology, Barretos Cancer Hospital, Barretos, SP, Brazil; Department of Clinical Research, Biohit HealthCare Plc., Helsinki, Finland.
Reference: Anticancer Res. 2015 May;35(5):2881-6.